![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 30, 2021
A focus on leukemia trials; an update regarding advanced practice providers; two important topics related to patient communication
September 30, 2021
This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021
Removing one of several steps will help speed the process for identifying patients who may be eligible to enroll for treatment in NCI-MATCH
September 30, 2021
A new Language Guide provides guidelines on best practices with common phrases to use during presentations at medical conferences and within submitted abstracts
September 30, 2021
The ethical imperative is that we must not treat the patient as a mere subject but as a participant partner, who therefore has rights to information about the trial to which they contributed
September 30, 2021
This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
September 30, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more